Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

112.46 +8.96 (+8.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Why BioNTech Stock Crushed the Market Today
The company might be close to commercializing its most advanced pipeline program. 
Via The Motley Fool
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.?
It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure. 
Via Investor's Business Daily
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study. 
Via Investor's Business Daily
Why Did BioNTech Stock Surge 10% Pre-Market Today?
Via Stocktwits
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population
Via Stocktwits
Breaking Down BioNTech: 12 Analysts Share Their Views
 
Via Benzinga
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push
Via Stocktwits
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China. 
Via Benzinga
Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works
Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest. 
Via Benzinga
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio?
Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades. 
Via Benzinga
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing. 
Via Benzinga
Earnings Scheduled For August 4, 2025
 
Via Benzinga
A Look Ahead: BioNTech's Earnings Forecast
 
Via Benzinga
RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles.
Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday. 
Via Investor's Business Daily
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic. 
Via Benzinga
Topics Government
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive. 
Via The Motley Fool
Topics Earnings
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy. 
Via Benzinga
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage. 
Via Benzinga
These Analysts Revise Their Forecasts On BioNTech After Q2 Results
 
Via Benzinga
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings: Revenue Surges 68.5%, Losses Narrower Than Expected
BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances. 
Via Chartmill
Topics Earnings
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Moderna's Key Patent Win Overshadowed By Gloomy Outlook
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce. 
Via Benzinga
Topics Intellectual Property
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion
Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings. 
Via Benzinga
Where Will Pfizer (PFE) Be in 5 Years?
The big drugmaker should be even bigger over the next five years despite facing a patent cliff. 
Via The Motley Fool
Topics Intellectual Property
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
Via Benzinga
Breaking Down BioNTech: 12 Analysts Share Their Views
 
Via Benzinga
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute. 
Via Benzinga
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.